Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07813572) titled 'ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular' on Sept. 4.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Condition:
Hepatocellular Carcinoma
Intervention:
Drug: ZG005 for Injection
Drug: Bevacizumab ( Avastin)
Drug: Sintilimab
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: September 2026
Target Sample Size: 600
Countries of Recruitment:
China
T...